Emergent BioSolutions Inc. (EBS) Financial Analysis & Valuation | Quarter Chart

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biolo... more
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and re... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$348.28MExchangeNYSE
SectorHealthcareIndustryBiotechnology
CountryUSCEOJoseph C. Papa Jr.
IPO Date2006-11-15CAGR12.36%
Employees900Websitewww.emergentbiosolutions.com
Div. YieldPayout Ratio
Buy Back Yield5.51%Total Yield5.51%
EBS chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$948.81MP/E4.69Forward P/E6.08PEG
P/S0.92P/B1.89P/CF25.56P/FCF47.73
Sales$770.20MSales 1Y-9.56%Sales 3Y-28.17%Sales 5Y-54.92%
EPS$1.44EPS 1Y-245.32%EPS 3Y-70.65%EPS 5Y-164%
Sales QoQ50.1%EPS QoQ-4797.17%Sales QoQ Avg20.86%EPS QoQ Avg-1408.06%
Gross Margin49.4%Operating Margin-7.06%Profit Margin-22.96%ROCE-5.47%
ROA-16%ROE-36%Altman Z Score0.84Piotroski Score6
Current Ratio5.42Quick Ratio2.95Cash Ratio1.14Op. CF Ratio-0.13
Debt/Equity1.7Debt/Assets0.52Lt Debt/Equity1.7Lt Debt/Cap.0.63
Intrst Cov.-1.07Inventory Turnover1.28Asset Turnover0.69Receivables Turnover4.05
Enterprise Value$948.81MP/E Ratio4.69
Forward P/E6.08PEG Ratio
P/S Ratio0.92P/B Ratio1.89
P/CF Ratio25.56P/FCF Ratio47.73
EPS$1.44EPS Growth 1Y-245.32%
EPS Growth 3Y-70.65%EPS Growth 5Y-164%
Revenue Growth 1Y-9.56%Gross Margin0.49%
Operating Margin-0.07%Profit Margin-0.23%
ROE-0.36%ROA-0.16%
ROCE-0.05%Current Ratio5.42
Quick Ratio2.95Cash Ratio1.14
Debt/Equity1.7Interest Coverage-1.07
Altman Z Score0.84Piotroski Score6

Emergent BioSolutions Inc. (EBS) valuation & financials

Emergent BioSolutions Inc. (EBS) has a market capitalization of $348.28M and trades at a price-to-earnings ratio of 4.7. It operates in the Healthcare sector (Biotechnology).

Emergent BioSolutions Inc.'s revenue grew -9.6% over the last year.

Emergent BioSolutions Inc.'s next earnings report is scheduled for November 4, 2026 after market close; analysts estimate EPS of $-0.37. Check the earnings calendar to see all companies reporting this week.

📈 Analysts estimate EBS EPS of $-0.37 for the upcoming quarter. See Emergent BioSolutions Inc. revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

Emergent BioSolutions Inc. (EBS) — frequently asked questions

When does Emergent BioSolutions Inc. (EBS) report earnings next?

Emergent BioSolutions Inc. is expected to report earnings on November 4, 2026 after market close. Analysts estimate EPS of $-0.37.

What is Emergent BioSolutions Inc.'s market cap?

Emergent BioSolutions Inc. (EBS) has a market capitalization of $348.28M.

What is EBS's P/E ratio?

Emergent BioSolutions Inc. trades at a price-to-earnings ratio of 4.7, with trailing twelve-month EPS of $1.44.

How fast is Emergent BioSolutions Inc. growing?

Emergent BioSolutions Inc.'s revenue grew -9.6% over the last year.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)